JP2003534286A5 - - Google Patents

Info

Publication number

JP2003534286A5

JP2003534286A5 JP2001585787A JP2001585787A JP2003534286A5 JP 2003534286 A5 JP2003534286 A5 JP 2003534286A5 JP 2001585787 A JP2001585787 A JP 2001585787A JP 2001585787 A JP2001585787 A JP 2001585787A JP 2003534286 A5 JP2003534286 A5 JP 2003534286A5

Authority

JP

Japan

Prior art keywords

therapeutic agent

arginine

salt

agent according

proanthocyanidin

Prior art date

2001-05-24

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000003814 drug Substances 0.000 description 8
• 229940124597 therapeutic agent Drugs 0.000 description 7
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
• ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 5
• 229930064664 L-arginine Natural products 0.000 description 5
• 235000014852 L-arginine Nutrition 0.000 description 5
• 150000003839 salts Chemical class 0.000 description 5
• JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 description 4
• 229920001991 Proanthocyanidin Polymers 0.000 description 4
• 208000010228 Erectile Dysfunction Diseases 0.000 description 3
• 201000001881 impotence Diseases 0.000 description 3
• 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
• 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 2
• 230000003511 endothelial effect Effects 0.000 description 2
• BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 1
• 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 1
• 230000015572 biosynthetic process Effects 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 230000000694 effects Effects 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 238000000034 method Methods 0.000 description 1
• 229960003310 sildenafil Drugs 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 239000000126 substance Substances 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1